-
-
-
-
-
-
-
Raymond James Reiterates Outperform Rating on Regenxbio Inc. (RGNX)
-
-
-
-
-
-
-
Regenxbio Inc. (RGNX) PT Lowered to $34 at H.C. Wainwright
-
-
-
-
-
-
-
New Research Reveals Emergence of New Variants of Coronavirus to Boost COVID-19 Therapeutics Market Growth
-
-
-
-
-
-
-
REGENXBIO Reports Fourth Quarter and Full Year 2023 Financial Results and Recent Operational Highlights
-
-
-
-
-
-
-
REGENXBIO to Host Conference Call on August 2 to Discuss Second Quarter 2023 Financial Results and Recent Operational Highlights
-
-
-
-
-
-
-
REGENXBIO Reports Third Quarter 2022 Financial Results and Recent Operational Highlights
-
-
-
-
-
-
-
REGENXBIO Reports Fourth Quarter and Full-Year 2021 Financial Results and Recent Operational Highlights
-
1,168,522 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

